News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
NicOx SA’ Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen
November 12, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SOPHIA ANTIPOLIS, FRANCE--(Marketwire - November 12, 2008) - New analysis of the 104 ABPM study presented at the American Heart Association
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
MORE ON THIS TOPIC
Autoimmune disease
Nektar Digs Into Mid-Stage Data to Establish Alopecia Efficacy of Rezpeg
December 17, 2025
·
2 min read
·
Tristan Manalac
Podcast
Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets
December 17, 2025
·
2 min read
·
Heather McKenzie
Insights
Uptick in Dealmaking, Chinese Partnerships Drive Biotech’s Comeback
December 17, 2025
·
3 min read
·
Jennifer Smith-Parker
Rare diseases
Kyverna’s CAR T Therapy Delivers ‘Impressive’ Mobility Benefits in Stiff Person Syndrome
December 16, 2025
·
2 min read
·
Tristan Manalac
